- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT07610928
Stress Management and Meditative Movements for Asian Americans With Depression and Physical Symptoms
10. Juli 2026 aktualisiert von: Albert Yeung, Massachusetts General Hospital
Integrating the Stress Management and Resiliency Training (SMART) With Qigong/Tai Chi (QTC) to Develop a Holistic Treatment for Asian Americans With Depression and Distressing Somatic Symptoms
Many Asian Americans with depression also struggle with physical symptoms-such as pain, fatigue, or other forms of bodily discomfort-that occur at the same time.
Right now, there is no proven treatment that effectively addresses both the depression and these physical symptoms together.
This study will test whether it is practical, acceptable, and safe to combine the Stress Management and Resiliency Training (SMART) program with meditative movements for people who have both major depression and these distressing physical symptoms.
Studienübersicht
Status
Noch keine Rekrutierung
Intervention / Behandlung
Studientyp
Interventionell
Einschreibung (Geschätzt)
70
Phase
- Unzutreffend
Teilnahmekriterien
Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.
Zulassungskriterien
Studienberechtigtes Alter
- Erwachsene
- Älterer Erwachsener
Akzeptiert gesunde Freiwillige
Nein
Beschreibung
Inclusion Criteria:
- Self-identify as being of Asian ethnicity
- English language proficiency
- Be ≥18 years of age
- Satisfy DSM-5 criteria for MDD prior to the initiation of the study intervention, as determined by a clinical interview conducted by the Principal Investigator (PI) during screening using DSM-5 diagnostic criteria.
- A baseline of the Patient-Reported Outcomes Measurement Information System (PROMIS) Depression score ≥ 16
- A baseline score of PHQ-15 ≥10
- Have not had Tai Chi/Qigong training/practice or other forms of mind-body intervention (e.g. yoga, mindfulness training, muscle relaxation training, etc) more than once a week in the past 3 months
- A total score 24 or higher in Mini-Mental Status Examination for cognitive ability (if the participant endorses a history of cognitive impairment).
- Willing to keep any psychiatric medications and psychotherapy stable throughout the course of the study (from Week 0 baseline to Week 12 Follow-up)
- Have access to a device (i.e., smartphone, iPad, personal computer) and a stable network to attend the online group sessions
- Ability to perform daily physical activity
Exclusion Criteria:
- Have a primary psychiatric diagnosis other than MDD
- Any history of psychosis, mania, or impulsivity and difficulty relating to people and judged by the clinician not appropriate for group intervention
- Active eating disorder or substance use disorder within the last 6 months
- Any relevant medical conditions that may be the medical basis of depression including thyroid diseases, epilepsy, history of an abnormal EEG, severe head trauma, or stroke
- Have serious uncontrolled medical conditions (e.g. poorly controlled diabetes, severe congestive heart failure), or other medical conditions that in the opinion of the investigators represents a risk to the subject, including presence of a pacemaker, cardiac arrhythmia, fever, weakness and hypotension, or vagal nerve stimulator
- current active suicidal or self-injurious potential (i.e., PHQ-9 item 9 ≥1 and/or a positive response to C-SSRS screener items 3, 4, 5, or 6), and assessed by the clinician necessitating immediate treatment
- Participant who are or who plan to receive confounding treatments (including treatment of endocrinopathies): use of antidepressants, complementary and alternative medical (CAM) treatments thought to have beneficial effects on mood, including St. John's Wort, S-Adenosyl methionine (SAMe), omega-3 fatty acids, light therapy, conventional psychotherapy, mind-body interventions (e.g. Qigong, mindfulness training, muscle relaxation training, etc.)
- Electroconvulsive therapy (ECT) during the last year as these patients are often among the more refractory and are not optimal candidates for CAM
- History of refractory to treatment with ≥3 failed antidepressant trials in current depressive episode
- Participated in other depression-related clinical trials within the past 3 months
- Antidepressant or psychiatric medications that are initiated less than 8 weeks or a dose change less than 4 weeks prior to screening visit
- Psychotherapy that has been initiated within the past 3 months
Studienplan
Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Single
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Aktiver Komparator: Healthy Living Program
|
The Healthy Living Program is an 8-session program designed to incorporate psychoeducation on a range of key health behaviors and wellness topics, including: the comorbidity between mental and physical illness, sleep, physical exercise, nutrition, and managing health-care needs.
The course encourages in-group and at-home self-monitoring and practice of healthy living principles.
|
|
Experimental: SMART-QTC
|
The SMART-QTC will be an 8-session online intervention with 1.5-hour weekly sessions that include core elements of SMART, including mind-body practice based on RR training, cognitive behavioral skills, and positive psychological skills, with QTC exercises incorporated at the end of every session.
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Feasibility of Recruitment, Eligibility Criteria, SMART-QTC and Control Interventions, and Videoconferencing Procedures
Zeitfenster: From screening to the end of assessments at week 12
|
Recruitment feasibility targets are: >=70% consent to screening, >=70% meeting screening criteria, >=70% of eligible individuals enrolling, and enrollment of >=20 participants/month.
Eligibility feasibility will include the proportion ineligible due to each criterion (<20%), reasons for ineligibility, reasons for refusal, and characteristics of refusers.
SMART-QTC and control intervention feasibility will include adherence (>=75% session attendance), retention (>=75% completion of post-assessments and >=70% completion of follow-up assessments), fidelity (checklist score >=80%), and home practice completion (>=75% completing home practice at least 3 days/week).
Videoconferencing feasibility will include <20% dropped connections, <20% missed sessions due to technical problems, mean number of technical problems <2.0, types of technical problems, and <20% requesting extra training, type of extra training needed.
|
From screening to the end of assessments at week 12
|
|
Acceptability of SMART-QTC and Control Interventions and Videoconferencing Procedures
Zeitfenster: From enrollment to the end of assessments at week 12
|
Acceptability of SMART-QTC and control interventions will be assessed using post-session surveys, post-intervention surveys, exit interviews, and follow-up surveys.
Outcomes include session satisfaction, helpfulness, enjoyment, relevance, and utility of each session component rated on a 5-point scale (1=not at all to 5=very much; mean >=3.75).
Overall program satisfaction, likelihood of continued skill use, and willingness to recommend the program to others will also target mean ratings >=3.75 on a 5-point scale.
Exit interviews will assess likes, dislikes, and suggestions for improvement.
>=60% of participants continuing meditation practice at follow-up.
Videoconferencing acceptability will include ease and confidence of use (1=not at all, 5=extremely, mean >=3.75), interference of technical problems (1=none, 5=extreme, mean <1.0), audiovisual quality and overall satisfaction (1=poor, 5=excellent, mean>=3.75),
and pros and cons and suggestions for improvement.
|
From enrollment to the end of assessments at week 12
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Patient Health Questionnaire-15 (PHQ-15)
Zeitfenster: From screening to the end of assessments at week 12
|
Somatic symptom severity will be assessed using the Patient Health Questionnaire-15 (PHQ-15), a 15-item self-report measure of physical symptom burden experienced over the past 7 days.
Each symptom is scored on a 3-point scale (0-2).
Total scores range from 0 to 30, with higher scores indicating greater somatic symptom severity and worse physical symptom burden.
|
From screening to the end of assessments at week 12
|
|
Patient-Reported Outcomes Measurement Information System (PROMIS) Emotional Distress-Depression-Short Form
Zeitfenster: From screening to the end of assessments at week 12
|
Depressive symptoms will be assessed using the PROMIS Depression Short Form, a self-report measure assessing the frequency and severity of depressive symptoms.
Participants rate depressive symptoms experienced during the past 7 days on a 5-point scale ranging from 1 (never) to 5 (always).
Raw total scores range from 8 to 40, with higher scores indicating greater severity of depressive symptoms and worse depression.
|
From screening to the end of assessments at week 12
|
Mitarbeiter und Ermittler
Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.
Studienaufzeichnungsdaten
Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.
Haupttermine studieren
Studienbeginn (Geschätzt)
15. August 2026
Primärer Abschluss (Geschätzt)
31. März 2027
Studienabschluss (Geschätzt)
31. August 2027
Studienanmeldedaten
Zuerst eingereicht
7. Mai 2026
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
20. Mai 2026
Zuerst gepostet (Tatsächlich)
28. Mai 2026
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
13. Juli 2026
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
10. Juli 2026
Zuletzt verifiziert
1. Mai 2026
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- 2026P001034
- 1R34AT012922-01 (US NIH Stipendium/Vertrag)
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
NEIN
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Nein
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Nein
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .